This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) A compound of ~~the~~ formula I



I

wherein

R^1 is H, A or SO_2A,

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E is $R^2C{=}CR^4$ or $R^2R^3C{-}CR^4R^5$,

wherein

R^2, R^3, R^4 and R^5 are each, independently of one another,
A, cycloalkyl having from 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nN(R^6)Ar$, $(CH_2)_nN(R^6)Het$, $(CH_2)_nN(Ar)_2$, $(CH_2)_nN(Het)_2$, $(CH_2)_nCOOR^6$, $(CH_2)_nCOOAr$, $(CH_2)_nCOOHet$, $(CH_2)_nCON(R^6)_2$, $(CH_2)_nCON(R^6)Ar$, $(CH_2)_nCON(R^6)Het$, $(CH_2)_nCON(Ar)_2$, $(CH_2)_nCON(Het)_2$, $(CH_2)_nNR^6COR^6$, $(CH_2)_nNR^6CON(R^6)_2$, $(CH_2)_nNR^6SO_2A$, $(CH_2)_nSO_2N(R^6)_2$, $(CH_2)_nSO_2NR^6(CH_2)_mAr$, $(CH_2)_nSO_2NR^6(CH_2)_mHet$, $(CH_2)_nS(O)_wR^6$, $(CH_2)_nS(O)_wAr$, $(CH_2)_nS(O)_wHet$, $(CH_2)_nOOCR^6$, $(CH_2)_nHet$, $(CH_2)_nAr$, $(CH_2)_nCOR^6$,

$(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$, $(CH_2)_nS(CH_2)_mAr$, $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)CO(CH_2)_mHet$, $CH=N\text{-}OA$, $CH_2CH=N\text{-}OA$, $(CH_2)_nNHOA$, $(CH_2)_nCH=N\text{-}Het$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$, $(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$, $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$, $CH=CHCH_2NR^6Het$, $CH=CHCH_2N(R^6)_2$, $CH=CHCH_2OR^6$, $(CH_2)_nN(COOR^6)COOR^6$, $(CH_2)_nN(CONH_2)COOR^6$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^6)COOR^6$, $(CH_2)_nN(CH_2CONH_2)COOR^6$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^6COR^6$, $(CH_2)_nCHR^6COOR^6$, $(CH_2)_nCHR^6CH_2OR^6$, $(CH_2)_nOCN$ or $(CH_2)_nNCO$,

wherein

R^6 is, independently, H, A or cycloalkyl having from 3 to 7 carbon atoms,

Het is a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical which is unsubstituted or mono- or polysubstituted by A, Hal, NO_2, CN, OR^6, $N(R^6)_2$, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, $SO_2N(R^6)_2$, $S(O)_wA$ and/or $OOCR^6$,

Ar is an aromatic hydrocarbon radical having from 6 to 14 carbon atoms

which is unsubstituted or mono- or polysubstituted by A, Hal, NO_2, CN, OR^6, $N(R^6)_2$, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, $SO_2N(R^6)_2$, $S(O)_wA$ and/or $OOCR^6$,

w is 0, 1, 2 or 3, and

n and m, independently of one another, are 0, 1, 2, 3, 4 or 5;

X^1 is $(CHR^7)_g$ ~~or $(CHR^7)_h$-Q-$(CHR^8)_k$~~, wherein

~~Q is O, S, N-R^6, $(O\text{-}CHR^7)_g$, $(CHR^7\text{-}O)_g$, $CR^9=CR^{10}$, $(O\text{-}CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}\text{-}O)_g$, C=O, C=S, C=$NR^6$, $CH(OR^6)$, $C(OR^6)(OR^6)$, C(=O)O, OC(=O), OC(=O)O, C(=O)N(R^6), N(R^6)C(=O), C(=S)N(R^6), N(R^6)C(=S), OC(=O)N(R^6), N(R^6)C(=O)O, CH=N-O, CH=N-NR^6, OC(O)NR^6, NR^6C(O)O, S=O, SO_2, SO_2NR^6 or NR^6SO_2,~~

g is 1, 2, 3, 4, 5 or 6,

~~h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6,~~

and

R^7, ~~R^8, R^9, R^{10}~~ and R^{12}, independently of one another, are as defined for R^2 to R^5;

p is 0, 1, 2 or 3,

E is H, A, $(CH_2)_n$Het, $(CH_2)_n$Ar or cycloalkyl having from 3 to 7 carbon atoms,

G is an optionally substituted alkylene radical having from 1 to 4 carbon atoms, where the substituents are selected from the meanings indicated for R^4,

or

E and G, together with the N atom to which they are bonded, are an unsubstituted or substituted 5-, 6- or 7-membered, mono- or bicyclic heterocyclic radical, which may have 1, 2 or 3 further heteroatoms selected from N, O and S,

X^2 is a bond ~~or is selected, independently, from the meanings indicated for X^+~~,

Z is H or is a saturated, mono- or polyethylenically unsaturated or aromatic carbocyclic radical having from 5 to 10 carbon atoms or a saturated, mono- or polyethylenically unsaturated or aromatic heterocyclic radical having from 4 to 9 carbon atoms, where the carbocyclic or heterocyclic radical may be mono- or polysubstituted, where the substituents ~~are~~, independently of one another, comprise the meanings of R^2 to R^5 other than H, and wherein the heterocyclic radical contains from 1 to 4 heteroatoms which is, independently of one another, N, O or S,

and

Hal is F, Cl, Br or I,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 2. (Currently Amended) The compound of ~~the~~ formula I according to Claim 1, wherein

A is straight-chain alkyl having from 1 to 4 carbon atoms or branched alkyl having from 3 to 6 carbon atoms, and

D-E is $R^2C=CR^4$ or $R^2R^3C\text{-}CR^4R^5$,
in which R^2, R^3 and R^5 are ~~selected~~, independently, ~~from~~ A or ~~and~~ cycloalkyl having from 3 to 7 carbon atoms,
and

R^4 is Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nCOOR^6$,

$(CH_2)_nCON(R^6)_2$, $(CH_2)_nNR^6COR^6$, $(CH_2)_nNR^6CON(R^6)_2$, $(CH_2)_nNR^6SO_2A$, $(CH_2)_nSO_2N(R^6)_2$, $(CH_2)_nS(O)_wA$, $(CH_2)_nOOCR^6$, $(CH_2)_nCOR^6$, $(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$, $(CH_2)_nS(CH_2)_mAr$, $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)CO(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$, $(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$, $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$, $(CH_2)_nN(COOR^6)COOR^6$, $(CH_2)_nN(CONH_2)COOR^6$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^6)COOR^6$, $(CH_2)_nN(CH_2CONH_2)COOR^6$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^6COR^6$, $(CH_2)_nCHR^6COOR^6$ or $(CH_2)_nCHR^6CH_2OR^6$,

m is 0, 1, 2, 3, 4 or 5 and

n 0 or 1;

X^1 is $(CHR^7)_g$ wherein ~~or Q $(CHR^8)_h$, in which~~

~~Q is selected from O, S, N-R^6, $(O\text{-}CHR^7)_g$, $(CHR^7\text{-}O)_g$, $CR^9{=}CR^{10}$, $(O\text{-}CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}\text{-}O)_g$, C=O, C=S, C=N$R^6$, C($OR^6$)($OR^6$), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R^6), N(R^6)C(=O),~~

~~OC(=O)N(R^6), N(R^6)C(=O)O, CH=N-O, CH=N-NR^6, OC(O)NR^6, NR^{6}C(O)O, S=O, SO$_2$, SO$_2$NR^6 and NR^{6}SO$_2$,~~

g is 2, 3 or 4,

k is 1, 2 or 3, and

R^7, R^8, R^9 and R^{10} ~~are selected,~~ independently, ~~from~~ comprises the meanings indicated for R^2 to R^5;

X^2 is a bond ~~or independently is $(CHR^7)_g$ or Q $(CHR^8)_k$, in which~~

~~Q is selected from O, S, N R^6, $(O\text{-}CHR^7)_g$, $(CHR^7\text{-}O)_g$, $(O\text{-}CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}\text{-}O)_g$, C=O, CH(OR^6), C(=O)O, OC(=O), C(=O)N(R^6), N(R^6)C(=O), S=O, SO$_2$, SO$_2$NR^6 and NR^{6}SO$_2$, where g in X^2 is 1 or 2 and k in X^2 is 0 or 1~~, and

R^{12} ~~is selected~~, independently, ~~from~~ comprises the meanings of R^4 ~~other than H~~,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 3. (Currently Amended) The compound according to Claim 1, of formula Ia,



Ia

wherein

R^1, D-E and Z are as defined in claim 1 ~~above~~, and wherein

X^1 is $(CHR^7)_g$ ~~or $(CHR^7)_h$-Q-$(CHR^8)_k$~~, wherein

~~Q is O, S, N-R^6, $(O-CHR^7)_g$, $(CHR^7-O)_g$, $CR^9=CR^{10}$, $(O-CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}-O)_g$, C=O, C=S, C=NR^6, $CH(OR^6)$, $C(OR^6)(OR^6)$, C(=O)O, OC(=O), OC(=O)O, C(=O)N(R^6), N(R^6)C(=O), OC(=O)N(R^6), N(R^6)C(=O)O, CH=N-O, CH=N-NR^6, OC(O)NR^6, NR^6C(O)O, S=O, SO_2, SO_2NR^6 or NR^6SO_2,~~

g is 1, 2, 3, 4, 5 or 6,

~~h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6, and~~

~~R^6 is selected, independently, from H, A or cycloalkyl having from 3 to 7 carbon atoms,~~

R^7, ~~R^8, R^9 and R^{10}~~ ~~are selected,~~ independently, ~~from~~ comprises the meanings indicated for R^2 to R^5;

Y is CH, N, COR^{11}, CSR^{11}, an unsubstituted or substituted, spiro-linked carbocyclic radical having from 5 to 7 carbon atoms or an unsubstituted or substituted, spiro-linked, 5-, 6- or 7-membered heterocyclic radical having from 1 to 3 heteroatoms ~~selected from~~ which are N, S or O,

R^{11} is H, A, $(CH_2)_n$Het, $(CH_2)_n$Ar or cycloalkyl having from 3 to 7 carbon atoms,

X^2 is a bond ~~or O, S, N-R^7, CH_2 or CH_2CH_2~~,

p, q and r, independently of one another, are 0, 1, 2 or 3

and

Hal is F, Cl, Br or I, and

R^{12} and R^{13}, are each, independently of one another, Hal, CN, NO_2, OR^6, $N(R^6)_2$,

NO_2, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ ~~and/or~~ or C(NH)NOH,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 4. (Previously Presented) A compound which is

a) 6-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

b) 6-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

c) 6-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

d) 4-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

e) 4-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

f) 4-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

g) 5-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

h) 5-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

i) 5-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

j) 5-{3-[4-(4-cyanophenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

k) 5-{4-[3-(3-cyano-1H-indol-6-yl)propyl]piperazin-1-yl}benzofuran-2-carboxamide;

l) 5-{3-[4-(2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

m) 5-{4-[3-(3-cyano-1H-indol-4-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;

n) 5-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;

o) 5-{3-[4-(1H-indol-4-yl)-piperazin-1-yl]propyl}-1-methanesulfonyl-1H-indole-3-carbonitrile;

p) 5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;

q) 5-[3-(4-benzo[1,2,5]thiadiazol-4-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

r) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carboxamide;

s) 5-[3-(4-quinolin-8-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

t) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

u) 1-methanesulfonyl-5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4 5]dec-8-yl)-propyl]-1H-indole-3-carbonitrile;

v) 5-{3-[4-(1H-indol-4-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

w) 5-{3-[4-(1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

x) 5-{3-[4-(5-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

y) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carbonitrile,

z) 5-{3-[4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

aa) 5-{3-[4-(4-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

bb) 5-[3-(4-benzo[d]isothiazol-3-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

cc) 4-{1-[3-(3-cyano-1H-indol-6-yl)propyl]piperidin-4-yloxy}benzamide;

dd) 6-{3-[4-(2-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

ee) 6-{3-[4-(4-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

ff) 6-{3-[4-(4-cyano-2-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

gg) 4-[3-(4-pyrazol-1-ylmethyl-1-piperidyl)propyl]-1H-indole-3-carbonitrile;

hh) N-(6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)acetamide;

ii) 5-{3-[(pyridin-3-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;

jj) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

kk) 5-[3-(4-pyrimidin-2-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

ll) 5-{3-[(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;

mm) 5-{3-[4-(3-methoxyphenyl)-3-methylpiperazin-1-yl]propyl}-1H-indole-3-carbonitrile,

nn) 5-{3-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]-propyl}-1H-indole-3-carbonitrile;

oo) N-(4-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-ylmethyl}-phenyl)acetamide;

pp) 5-{3-[4-(4-pyridin-3-ylthiazol-2-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

qq) ethyl 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-thiazole-4-carboxylate;

rr) 5-{3-[3-(2-oxopyrrolidin-1-yl)propylamino]propyl}-1H-indole-3-carbonitrile;

ss) ethyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate;

tt) 5-{3-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

uu) methyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate;

vv) 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]-piperazin-1-yl}thiazole-4-carboxamide; or

ww) 4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazine-1- thiocarboxamide;

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 5. (Currently Amended) A process for the preparation of a compound of formula I according to Claim 1 or a salt thereof comprising reacting

a) a compound of ~~the~~ formula II



II

wherein

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R^1, D, E, R^{12}, p and X^1 are as defined in Claim 1,

b) with a compound of ~~the~~ formula III



III

wherein

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1,

and optionally

c) converting the resultant compound of ~~the~~ formula I into a salt by treatment with an acid.

Claim 6. (Previously Presented) A process for the preparation of a pharmaceutical composition, comprising converting a compound of Claim 1 into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

Claim 7. (Previously Presented) A pharmaceutical composition comprising at least one compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 8. (Cancelled)

Claim 9. (Previously Presented) A method for inhibiting the activity of an excitatory amino acid in a cell, comprising contacting said cell with a compound of claim 1.

Claim 10. (Previously Presented) A method for inhibiting the activity of a glycine transporter comprising contacting said transporter with a compound of claim 1.

Claim 11. (Cancelled)

Claim 12. (Previously Presented) A method for treating a 5HT-mediated disease comprising administering to a host in need thereof a compound of claim 1.

Claim 13. (Currently Amended) ~~A~~ The method according to Claim 12, wherein said disease is depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, brain and spinal cord trauma, obsessive-compulsive disorder, sleeping disorder ~~disorders~~, tardive dyskinesia, learning disorder ~~disorders~~, age-related memory disorder ~~disorders~~, eating disorder ~~disorders~~, ~~and/or~~ or sexual dysfunction ~~dysfunctions~~.

Claim 14. (Previously Presented) A method for treating schizophrenia, depression, dementia, Parkinson's disease, Alzheimer's disease, Lewy bodies dementia, Huntington's disease, Tourette's syndrome, anxiety, learning and memory impairments, neurodegenerative diseases, cognitive impairments, nicotine dependence or pain comprising administering to a host in need thereof a compound of claim 1.

Claim 15. (Previously Presented) A method for combating neurodegenerative diseases, cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a compound of claim 1.

Claim 16. (Previously Presented) A method for combating neurodegenerative diseases, cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a

host in need thereof a pharmaceutical composition of claim 7.

Claim 17. (Cancelled)

Claim 18. (Withdrawn, Currently Amended) A compound of ~~the~~ formula II



II

wherein

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R^1, D, E, R^{12}, p and X^1 are as defined in Claim 1.

Claim 19. (Withdrawn, Currently Amended) A compound of ~~the~~ formula III



III

wherein

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1.

Claim 20. (Currently Amended) A compound of ~~the~~ formula Ia



Ia

wherein

R^1 is H, A or SO_2A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 1, 2, 3, 4, 5 or 6,

R^7 is ~~selected~~, independently, ~~from~~ has the meanings indicated for R^2 to R^5;

Y is CH or N,

q is 0,

p and r are each, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13}, are each, independently of one another, ~~are selected from the meanings of~~ R^4 ~~other than H and~~ or are, independently of one another, Hal, CN, NO_2, OR^6, $N(R^6)_2$, NO_2, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ ~~and/or~~ or C(NH)NOH, and

X^2-Z is at least one of ~~selected from the group consisting of~~





wherein

X^2 is a bond,

R^{14} is ~~selected~~, independently, ~~from~~ Hal, A, $(CH_2)_nHet$, $(CH_2)_nAr$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nNHOA$, $(CH_2)_n(R^6)Het$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, or CN

w is 0, 1, 2 or 3,

t is 0, 1, 2, 3, 4 or 5, and

m is 0, 1, 2, 3, 4, or 5

n is 0, 1, 2, or 3

R' is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon atoms or SO_2A;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof

Claim 21. (Currently Amended) A compound of ~~the~~ formula IIa



IIa

wherein R^1 and R^2 are as defined in claim 20; and

Y-Z is a radical which comprises at least one of ~~the formulae~~



or a radical which comprises at least one of ~~the formulae~~



or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.

Claim 22. (Currently Amended) A compound of ~~the~~ formula Ia according to claim 20



Ia

wherein

R^1 is H or A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^3$, wherein R^2 is H or methyl and R^3 is CN

X^1 is $(CHR^7)_g$

g is 3,

R^7 ~~is selected~~, independently, ~~from~~ has the meanings indicated for R^2 to R^5;

Y is CH or N,

q is 0,

p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13}, are, independently of one another, Hal, CN, NO_2, OR^6, $N(R^6)_2$, NO_2, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ ~~and/or~~ or C(NH)NOH, and

X^2-Z is at least one of ~~selected from the group consisting of~~





wherein

X^2 is a bond,

R^{14} is ~~selected~~, independently, ~~from~~ Hal, NO_2, OR^6, $N(R^6)_2$, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COK^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ and/or C(NH)NOH,

w is 0, 1, 2 or 3,

t is 1, 2, 3, and

R' is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon atoms or SO_2A;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.